<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02037425</url>
  </required_header>
  <id_info>
    <org_study_id>13-002AL</org_study_id>
    <nct_id>NCT02037425</nct_id>
  </id_info>
  <brief_title>Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine</brief_title>
  <official_title>Exploratory Study of the Natural History, Clinical Outcomes, and Neuronal Endplate Changes in Subjects Reporting Short Duration vs. Long Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cady, Roger, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cady, Roger, M.D.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To obtain a patient specific understanding of response to treatment with onabotulinumtoxinA
      by collecting and correlating pre and post treatment subject specific history, clinical
      outcomes, and histological changes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recognizing a commitment to evidence-based science as the pathway to optimize clinical
      outcomes for patients with chronic migraine (CM) we believe this investigator initiated study
      (IIS) will:

        1. Help clinicians recognize the importance of scheduling patients with CM at intervals not
           exceeding 12 weeks.

        2. Provide biopsy evidence supporting sensory mechanisms involved in the mechanism of
           action (MOA) of onabotulinumtoxinA (BTX). This does not exclude potential valuable
           contributions of denervation of motor neurons, but may support a more balanced and
           understandable mechanism for BTX in treating CM.

        3. Provide clinicians important educational information for patients to better manage
           expectations of using BTX in managing CM and answering critical questions such as:

             1. How long does it take for BTX to begin providing a clinical benefit?

             2. What is the expected duration of this benefit?

                  -  Failure to understand unmet expectations either real or otherwise results in
                     defining BTX treatment as a failure by patients and/or clinicians.

        4. Provide validation for patients' reports of shorter duration of action of BTX so
           patients will not be misinterpreted as non-responders to BTX prematurely.

        5. Ascertain if subjects initially reporting short duration of BTX response continue to
           experience this similar pattern of effect with repeated injection cycles.

        6. Provide the first detailed longitudinal assessment of BTX response.

        7. Correlate the onset and duration of benefit for subjects receiving BTX.

        8. Observe factors predictive of duration of BTX response.

      This study proposes to accomplish these goals through an exploratory comparison of the
      clinical efficacy and natural history of BTX measured at weekly time intervals. Subjects
      reporting short (&lt;10 weeks) duration of benefit and subjects reporting long (&gt;10 weeks)
      duration of clinical benefit will provide the primary comparison. Histological examinations
      (in a subset of subjects) of neuronal changes associated with regeneration of terminal
      neuronal endplates will be used to support these clinical observations. This study will
      follow subjects through 3 injection cycles or 36 weeks. Biopsies will be performed on
      consenting subjects prior to their first and second injection cycles.

      Group Assignment

      At Visit 3, subjects will be assigned to one of three groups (Groups A, B, C) based on their
      answers to the following questions:

        1. Since your last BTX treatment, do you think there has been improvement in your chronic
           migraine? If the answer to Q1 is yes, subject will answer Q2 and Q3. If the answer is
           no, subject is assigned to Group C and no further answers are required:

        2. How many days did it take for you to first notice benefit from BTX injections?

        3. How long did you feel you received benefit from BTX (number of weeks)?

      Subjects will be assigned into 3 groups:

        1. Group A are subjects reporting 10 or less weeks of benefit from BTX;

        2. Group B are subjects reporting &gt;10 weeks of benefit from BTX;

        3. Group C are subjects reporting no or minimal (&lt; 30%) benefit from BTX.

      Consistency of subjects' perception of BTX benefit at 12 weeks will be compared to responses
      at 24 and 36 weeks, though Group assignment will remain as defined at 12 weeks.

      This exploratory study will be conducted at the Headache Care Center in Springfield, MO.
      Thirty-six subjects, 18 years and older with a history of chronic migraine will be enrolled.
      The study will consist of 5 visits for all subjects.

      At Visit 1 (day 1 of baseline) the following study procedures will be performed:

        -  Informed Consent obtained

        -  Migraine, medical and medication history obtained

        -  Physical and neurological exam performed

        -  Urine pregnancy test performed if applicable

        -  Vital signs collected

      At Visit 2 (day 29 +/- 3 days) the following study procedures will be performed:

        -  Update medical and medication history

        -  Urine pregnancy test performed if applicable

        -  Vital signs collected

        -  Review baseline diary

        -  Complete Migraine Disability Assessment Scale (MIDAS)

        -  Complete Social Readjustment Rating Scale (SRRS)

        -  Complete Beck Depression Inventory II (BDI-II)

        -  Complete State-Trait Anxiety Inventory (STAI)

        -  Complete Sleep Quality Questionnaire

        -  Punch biopsy for neuronal regrowth (subset of subjects)

        -  onabotulinumtoxinA injections

      At Visit 3 (day 113 +/- 3 days) the following study procedures will be performed:

        -  Update medical and medication history

        -  Urine pregnancy test performed if applicable

        -  Vital signs collected

        -  Complete Subject Global Impression of Change (SGIC)

        -  Complete Physician Global Impression of Change (PGIC)

        -  Complete Migraine Disability Assessment Scale (MIDAS)

        -  Complete Social Readjustment Rating Scale (SRRS)

        -  Complete Beck Depression Inventory II (BDI-II)

        -  Complete State-Trait Anxiety Inventory (STAI)

        -  Complete Sleep Quality Questionnaire

        -  Complete duration of response to onabotulinumtoxinA questions

        -  Punch biopsy for neuronal regrowth (subset of subjects)

        -  onabotulinumtoxinA injections

      At Visit 4 (day 197 +/- 3 days) the following study procedures will be performed:

        -  Update medical and medication history

        -  Urine pregnancy test performed if applicable

        -  Vital signs collected

        -  Complete Subject Global Impression of Change (SGIC)

        -  Complete Physician Global Impression of Change (PGIC)

        -  Complete Migraine Disability Assessment Scale (MIDAS)

        -  Complete Social Readjustment Rating Scale (SRRS)

        -  Complete Beck Depression Inventory II (BDI-II)

        -  Complete State-Trait Anxiety Inventory (STAI)

        -  Complete Sleep Quality Questionnaire

        -  Complete duration of response to onabotulinumtoxinA questions

        -  onabotulinumtoxinA injections

      At Visit 5 (day 281 +/- 3 days) the following study procedures will be performed:

        -  Update medical and medication history

        -  Urine pregnancy test performed if applicable

        -  Vital signs collected

        -  Complete Subject Global Impression of Change (SGIC)

        -  Complete Physician Global Impression of Change (PGIC)

        -  Complete Migraine Disability Assessment Scale (MIDAS)

        -  Complete Social Readjustment Rating Scale (SRRS)

        -  Complete Beck Depression Inventory II (BDI-II)

        -  Complete State-Trait Anxiety Inventory (STAI)

        -  Complete Sleep Quality Questionnaire

        -  Complete duration of response to onabotulinumtoxinA questions
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject Global Impression of Change</measure>
    <time_frame>Weeks 12, 24, and 36 Post Randomization</time_frame>
    <description>Changes in the Subject's Global Impression of Change (SGIC) measured at weeks 12, 24, and 36 for Groups A, B, and C. Subject global impression of change was measured on a 7 point scale with 0 being Very Much Worse and 7 Very Much Improved.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of onabotulinumtoxinA Over 3 Injection Cycles in Groups A, B, and C</measure>
    <time_frame>From day 29 (first day of injection cycle 1) to day 281 (84th day of injection cycle 3) plus or minus 12 days</time_frame>
    <description>Compare the duration of onabotulinumtoxinA response through the 3 injection cycles of the study for Groups A, B, and C as measured by headache days during each period (Baseline (28 days), Treatment Period 1(84 days), Treatment Period 2(84 days), and Treatment Period 3(84 days). Duration of response is defined as a 30% reduction in the number of headache days compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Headache Days</measure>
    <time_frame>From day 29 (first day of injection cycle 1) to day 281 (84th day of injection cycle 3) plus or minus 12 days</time_frame>
    <description>Comparison of headache days per month over each injection cycle between Groups A, B, and C (Baseline (28 days), Treatment Period 1(84 days), Treatment Period 2(84 days), and Treatment Period 3(84 days). Subjects will remain in their assigned groups based on assessment at 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Migraine Disability Assessment Scale (MIDAS)</measure>
    <time_frame>Baseline, Week 12, Week 24, and Week 36 Post Randomization</time_frame>
    <description>Comparison between Group A, B, and C for MIDAS total scores (effect migraine headaches have on subjects daily function) measured at baseline and weeks 12, 24, and 36.
Total score of disability ranges:
0 to 5, MIDAS Grade I, Little or no disability
6 to 10, MIDAS Grade II, Mild disability
11 to 20, MIDAS Grade III, Moderate disability
21+, MIDAS Grade IV, Severe disability Score ranges from 0-450. No subscales are present.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social Readjustment Rating Scale (SRRS)</measure>
    <time_frame>Baseline, Week 12, Week 24, and Week 36 Post Randomization</time_frame>
    <description>Comparison between Group A, B, and C for SRRS scores (impact of common stressors) measured at baseline and weeks 12, 24, and 36. Scores can range from 0 to an undetermined amount, as subjects are allowed to rate unlisted events according to their own sense of stress. A total lower than 150 suggests a low level of stress and a low probability of developing a stress-related disorder. Scores greater than 150 suggest higher levels of stress and higher probabilities of developing stress-related disorders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Global Impression of Change (PGIC)</measure>
    <time_frame>Week 12, Week 24, and Week 36 Post Randomization</time_frame>
    <description>Comparison between Group A, B, and C for PGIC scores measured at weeks 12, 24, and 36. the PGIC scale scores range from 0-7 with 0 being Very Much Worse and 7 being Very Much Improved. A higher score indicates a greater impression of change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory II (BDI-II)</measure>
    <time_frame>Baseline, Week 12, Week 24, and Week 36 Post Randomization</time_frame>
    <description>Comparison between Group A, B, and C for BDI-II scores measured at baseline and weeks 12, 24, and 36. A total score of 0-10 = these ups and downs are considered normal, 11-16 = mild mood disturbance,17-20 = borderline clinical depression, 21-30 = moderate depression, 31-40 = severe depression, over 40 = extreme depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>State-Trait Anxiety Inventory (STAI)</measure>
    <time_frame>Baseline, Week 12, Week 24, and Week 36 Post Randomization</time_frame>
    <description>Comparison between Group A, B, and C for STAI scores measured at baseline and weeks 12, 24, and 36. Scores range from 20-80, with 20 indicating lower levels of anxiety most generally, and 80 indicating higher levels of anxiety most generally.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality Question</measure>
    <time_frame>Baseline, Week 12, Week 24, and Week 36 Post Randomization</time_frame>
    <description>Comparison between Group A, B, and C for sleep quality scores measured at baseline and weeks 12, 24, and 36 post-randomization. A single sleep quality question was asked indicating quality of sleep over the past four weeks. The scale ranged from 1-5, with 1 being very poor quality and 5 being very good quality of sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Medication Usage</measure>
    <time_frame>From day 1 (first day of baseline) to day 281 (84th day of injection cycle 3) plus or minus 12 days</time_frame>
    <description>Comparison of acute medication usage between Groups A, B, and C during baseline, Treatment Period 1, 2, and 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consistency of Response to onbotulinumtoxinA Over Three Injection Cycles</measure>
    <time_frame>Weeks 12, 24, and 36 Post Randomization</time_frame>
    <description>Compare the consistency of duration of onabotulinumtoxinA response by the group assignment at 12 weeks to assessments at 24, and 36 weeks evaluations as measured by the number of responders. A responder is defined as a 30% reduction from baseline in the number of headache days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of onabotulinumtoxinA Over 3 Injection Cycles</measure>
    <time_frame>Weeks 9, 10, 11, 12, 21, 22, 23, 24, 33, 34, 35, 36 Post Randomization</time_frame>
    <description>Compare duration of benefit of onabotulinumtoxinA response through 3 injection cycles as measured by headache days per week (including the last 4 weeks of every injection cycle). A percent of responders was calculated using a 30% reduction of the number of headache days compared to average number of headache per week during baseline.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Neuronal Regrowth</measure>
    <time_frame>Baseline &amp; Week 12 Post Randomization</time_frame>
    <description>Compare neuronal regrowth in the skin biopsies with duration of benefit of onabotulinumtoxinA in Groups A, B, C from baseline to 12 weeks post randomization. Neuronal regrowth change was scored on a 0-3 point scale with 0 being no change from baseline in regrowth and 3 being significant change from baseline.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Chronic Migraine</condition>
  <arm_group>
    <arm_group_label>onabotulinumtoxinA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>At visit 2, subjects will receive their first treatment at Day 29 (+/-3 days). All subjects will receive 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas. Injections will be repeated at day 113 (+/- 3 days) and at day 197 (+/- 3 days).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>onabotulinumtoxinA</intervention_name>
    <description>BOTOXÂ® (Formulation Number 9060X) contains 200 International Units (IU) of Clostridium botulinum Toxin Type A, reconstituted with 4 cc of normal saline providing 5 units per 0.1 cc. At visit 2, subjects will receive their first treatment at Day 29 (+/-3 days). All subjects will receive 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas. Injections will be repeated at day 113 (+/- 3 days) and at day 197 (+/- 3 days).</description>
    <arm_group_label>onabotulinumtoxinA</arm_group_label>
    <other_name>Botox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female 18 years or older.

          -  able to read, understand, and sign the informed consent.

          -  a negative urine pregnancy test at visit 1, if female, and of childbearing potential.
             Note: If female of childbearing potential, subject must agree to maintain true
             abstinence or use one of the listed methods of birth control for the duration of the
             study: hormonal contraceptive, intrauterine device (IUD), condoms, diaphragm, and/or
             have a male partner who has undergone a successful vasectomy. The use of barrier
             contraceptive (condom or diaphragm) should always be supplemented with the use of a
             spermicide.

        Note: To be considered not of childbearing potential, subject must be 6 weeks post-surgical
        bilateral oophorectomy, hysterectomy, bilateral tubal ligation, postmenopausal for at least
        one year.

          -  at least a one year history of migraine

          -  history of chronic migraine (with or without aura) according to the criteria of the
             International Classification of Headache Disorders (ICHD)-3 for at least 3 months
             prior to enrollment (Appendix I)

          -  able to differentiate migraine headache from any other headache they may experience
             (e.g., cluster headache)

          -  onset of migraine before age 50

          -  willing to provide responses to questionnaires and complete the online diary.

          -  if taking migraine preventive(s), be on a stable dose of the preventive medication for
             at least 30 days prior to screening

          -  concomitant medication dosages approved by the investigator

          -  email and internet access for completion of online diary

        Exclusion Criteria:

          -  previously used onabotulinumtoxinA as a migraine preventative or has used
             onabotulinumtoxinA for any other reason during the prior year

          -  female who is pregnant, planning to become pregnant during the study period, breast
             feeding, or is of childbearing potential and not practicing a reliable form of birth
             control

          -  headache disorders outside ICHD-3 defined chronic migraine that cannot be easily
             distinguished from CM (Appendix I)

          -  evidence of underlying pathology contributing to their headaches

          -  any medical condition that may increase their risk with exposure to BTX including
             diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or
             any other significant disease that might interfere with neuromuscular function

          -  profound atrophy or weakness of muscles in the target areas of injection

          -  skin conditions or infections at any of the injection sites

          -  allergy or sensitivities to any component of the test medication

          -  in the opinion of the investigator, has an active major psychiatric disorder including
             substance abuse and/or substance dependence within the last 12 months as determined by
             the investigator.

          -  Medication Overuse Headache as defined by ICHD-3 criteria for opioid or butalbital
             containing products (Appendix II)

          -  planning or requiring surgery during the study

          -  a history of poor compliance with medical treatment

          -  currently participating in an investigational drug study or has participated in an
             investigational drug study within the previous 30 days of the screening visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger K Cady, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinvest</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinvest/A Division of Banyan Group, Inc.</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2014</study_first_submitted>
  <study_first_submitted_qc>January 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2014</study_first_posted>
  <results_first_submitted>December 11, 2015</results_first_submitted>
  <results_first_submitted_qc>February 9, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 8, 2016</results_first_posted>
  <last_update_submitted>July 11, 2016</last_update_submitted>
  <last_update_submitted_qc>July 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Migraine</keyword>
  <keyword>onabotulinumtoxinA</keyword>
  <keyword>Headache</keyword>
  <keyword>Migraine</keyword>
  <keyword>Neuronal regrowth</keyword>
  <keyword>Botox</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>onabotulinumtoxinA</title>
          <description>At visit 2, subjects will receive their first treatment at Day 29 (+/-3 days). All subjects will receive 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas. Injections will be repeated at day 113 (+/- 3 days) and at day 197 (+/- 3 days).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Randomized to Treatment</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>44 subjects screened, 3 subjects failed inclusion/exclusion at screening, 9 subjects did not meet criteria after baseline. 32 subjects randomized to treatment. While 32 subjects randomized and were used for reporting demographics, two subjects didn't complete any outcome measures, therefore only 30 participants were used for endpoint analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>onabotulinumtoxinA</title>
          <description>At visit 2, subjects will receive their first treatment at Day 29 (+/-3 days). All subjects will receive 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas. Injections will be repeated at day 113 (+/- 3 days) and at day 197 (+/- 3 days). A total of 30 subjects were used in data analysis as 2 subjects did not complete any outcome measures once enrolled in the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.56" spread="9.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subject Global Impression of Change</title>
        <description>Changes in the Subject's Global Impression of Change (SGIC) measured at weeks 12, 24, and 36 for Groups A, B, and C. Subject global impression of change was measured on a 7 point scale with 0 being Very Much Worse and 7 Very Much Improved.</description>
        <time_frame>Weeks 12, 24, and 36 Post Randomization</time_frame>
        <population>Subjects included in this outcome measure analysis include those completing treatment period 1 injection cycle and returning at visit 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Subjects reporting 10 weeks or less of benefit from onabotuliunumtoxinA.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Subjects reporting greater than 10 weeks of benefit from onabotuliunumtoxinA.</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Subjects reporting no or minimal of benefit from onabotuliunumtoxinA (3 weeks or less).</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Global Impression of Change</title>
          <description>Changes in the Subject's Global Impression of Change (SGIC) measured at weeks 12, 24, and 36 for Groups A, B, and C. Subject global impression of change was measured on a 7 point scale with 0 being Very Much Worse and 7 Very Much Improved.</description>
          <population>Subjects included in this outcome measure analysis include those completing treatment period 1 injection cycle and returning at visit 3.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.43" spread="1.94"/>
                    <measurement group_id="O2" value="5.67" spread="0.47"/>
                    <measurement group_id="O3" value="1.67" spread="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.76" spread="1.38"/>
                    <measurement group_id="O2" value="5.33" spread="0.47"/>
                    <measurement group_id="O3" value="3.33" spread="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.14" spread="2.17"/>
                    <measurement group_id="O2" value="5.33" spread="0.47"/>
                    <measurement group_id="O3" value="2.50" spread="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Duration of onabotulinumtoxinA Over 3 Injection Cycles in Groups A, B, and C</title>
        <description>Compare the duration of onabotulinumtoxinA response through the 3 injection cycles of the study for Groups A, B, and C as measured by headache days during each period (Baseline (28 days), Treatment Period 1(84 days), Treatment Period 2(84 days), and Treatment Period 3(84 days). Duration of response is defined as a 30% reduction in the number of headache days compared to baseline.</description>
        <time_frame>From day 29 (first day of injection cycle 1) to day 281 (84th day of injection cycle 3) plus or minus 12 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Subjects reporting 10 weeks or less of benefit from onabotuliunumtoxinA.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Subjects reporting greater than 10 weeks of benefit from onabotuliunumtoxinA.</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Subjects reporting no or minimal of benefit from onabotuliunumtoxinA (3 weeks or less).</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of onabotulinumtoxinA Over 3 Injection Cycles in Groups A, B, and C</title>
          <description>Compare the duration of onabotulinumtoxinA response through the 3 injection cycles of the study for Groups A, B, and C as measured by headache days during each period (Baseline (28 days), Treatment Period 1(84 days), Treatment Period 2(84 days), and Treatment Period 3(84 days). Duration of response is defined as a 30% reduction in the number of headache days compared to baseline.</description>
          <units>percentage of responders</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Period 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Period 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Period 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Headache Days</title>
        <description>Comparison of headache days per month over each injection cycle between Groups A, B, and C (Baseline (28 days), Treatment Period 1(84 days), Treatment Period 2(84 days), and Treatment Period 3(84 days). Subjects will remain in their assigned groups based on assessment at 12 weeks.</description>
        <time_frame>From day 29 (first day of injection cycle 1) to day 281 (84th day of injection cycle 3) plus or minus 12 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Subjects reporting 10 weeks or less of benefit from onabotuliunumtoxinA.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Subjects reporting greater than 10 weeks of benefit from onabotuliunumtoxinA.</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Subjects reporting no or minimal of benefit from onabotuliunumtoxinA (3 weeks or less).</description>
          </group>
        </group_list>
        <measure>
          <title>Headache Days</title>
          <description>Comparison of headache days per month over each injection cycle between Groups A, B, and C (Baseline (28 days), Treatment Period 1(84 days), Treatment Period 2(84 days), and Treatment Period 3(84 days). Subjects will remain in their assigned groups based on assessment at 12 weeks.</description>
          <units>number of headache days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.95" spread="4.19"/>
                    <measurement group_id="O2" value="22.33" spread="2.36"/>
                    <measurement group_id="O3" value="24.83" spread="3.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Period 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.76" spread="19.80"/>
                    <measurement group_id="O2" value="37.0" spread="10.61"/>
                    <measurement group_id="O3" value="64.83" spread="11.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Period 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.06" spread="21.27"/>
                    <measurement group_id="O2" value="29.33" spread="12.66"/>
                    <measurement group_id="O3" value="55" spread="21.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Period 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.43" spread="22.0"/>
                    <measurement group_id="O2" value="29.33" spread="12.66"/>
                    <measurement group_id="O3" value="65.67" spread="22.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Migraine Disability Assessment Scale (MIDAS)</title>
        <description>Comparison between Group A, B, and C for MIDAS total scores (effect migraine headaches have on subjects daily function) measured at baseline and weeks 12, 24, and 36.
Total score of disability ranges:
0 to 5, MIDAS Grade I, Little or no disability
6 to 10, MIDAS Grade II, Mild disability
11 to 20, MIDAS Grade III, Moderate disability
21+, MIDAS Grade IV, Severe disability Score ranges from 0-450. No subscales are present.</description>
        <time_frame>Baseline, Week 12, Week 24, and Week 36 Post Randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Subjects reporting 10 weeks or less of benefit from onabotuliunumtoxinA.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Subjects reporting greater than 10 weeks of benefit from onabotuliunumtoxinA.</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Subjects reporting no or minimal of benefit from onabotuliunumtoxinA (3 weeks or less).</description>
          </group>
        </group_list>
        <measure>
          <title>Migraine Disability Assessment Scale (MIDAS)</title>
          <description>Comparison between Group A, B, and C for MIDAS total scores (effect migraine headaches have on subjects daily function) measured at baseline and weeks 12, 24, and 36.
Total score of disability ranges:
0 to 5, MIDAS Grade I, Little or no disability
6 to 10, MIDAS Grade II, Mild disability
11 to 20, MIDAS Grade III, Moderate disability
21+, MIDAS Grade IV, Severe disability Score ranges from 0-450. No subscales are present.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.19" spread="54.60"/>
                    <measurement group_id="O2" value="115.67" spread="55.26"/>
                    <measurement group_id="O3" value="74.33" spread="56.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.90" spread="14.44"/>
                    <measurement group_id="O2" value="25.67" spread="11.12"/>
                    <measurement group_id="O3" value="96.83" spread="70.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.65" spread="22.03"/>
                    <measurement group_id="O2" value="28.00" spread="5.89"/>
                    <measurement group_id="O3" value="66.33" spread="44.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.29" spread="28.35"/>
                    <measurement group_id="O2" value="30.33" spread="15.80"/>
                    <measurement group_id="O3" value="86.00" spread="40.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Social Readjustment Rating Scale (SRRS)</title>
        <description>Comparison between Group A, B, and C for SRRS scores (impact of common stressors) measured at baseline and weeks 12, 24, and 36. Scores can range from 0 to an undetermined amount, as subjects are allowed to rate unlisted events according to their own sense of stress. A total lower than 150 suggests a low level of stress and a low probability of developing a stress-related disorder. Scores greater than 150 suggest higher levels of stress and higher probabilities of developing stress-related disorders.</description>
        <time_frame>Baseline, Week 12, Week 24, and Week 36 Post Randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Subjects reporting 10 weeks or less of benefit from onabotuliunumtoxinA.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Subjects reporting greater than 10 weeks of benefit from onabotuliunumtoxinA.</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Subjects reporting no or minimal of benefit from onabotuliunumtoxinA (3 weeks or less).</description>
          </group>
        </group_list>
        <measure>
          <title>Social Readjustment Rating Scale (SRRS)</title>
          <description>Comparison between Group A, B, and C for SRRS scores (impact of common stressors) measured at baseline and weeks 12, 24, and 36. Scores can range from 0 to an undetermined amount, as subjects are allowed to rate unlisted events according to their own sense of stress. A total lower than 150 suggests a low level of stress and a low probability of developing a stress-related disorder. Scores greater than 150 suggest higher levels of stress and higher probabilities of developing stress-related disorders.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168.68" spread="108.77"/>
                    <measurement group_id="O2" value="157.00" spread="81.86"/>
                    <measurement group_id="O3" value="199.50" spread="161.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131.76" spread="115.98"/>
                    <measurement group_id="O2" value="168.33" spread="57.05"/>
                    <measurement group_id="O3" value="141.67" spread="99.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.33" spread="81.33"/>
                    <measurement group_id="O2" value="215.33" spread="163.94"/>
                    <measurement group_id="O3" value="122.50" spread="138.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.81" spread="93.02"/>
                    <measurement group_id="O2" value="221.00" spread="117.29"/>
                    <measurement group_id="O3" value="70.83" spread="87.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician Global Impression of Change (PGIC)</title>
        <description>Comparison between Group A, B, and C for PGIC scores measured at weeks 12, 24, and 36. the PGIC scale scores range from 0-7 with 0 being Very Much Worse and 7 being Very Much Improved. A higher score indicates a greater impression of change.</description>
        <time_frame>Week 12, Week 24, and Week 36 Post Randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Subjects reporting 10 weeks or less of benefit from onabotuliunumtoxinA.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Subjects reporting greater than 10 weeks of benefit from onabotuliunumtoxinA.</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Subjects reporting no or minimal of benefit from onabotuliunumtoxinA (3 weeks or less).</description>
          </group>
        </group_list>
        <measure>
          <title>Physician Global Impression of Change (PGIC)</title>
          <description>Comparison between Group A, B, and C for PGIC scores measured at weeks 12, 24, and 36. the PGIC scale scores range from 0-7 with 0 being Very Much Worse and 7 being Very Much Improved. A higher score indicates a greater impression of change.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.95" spread="1.05"/>
                    <measurement group_id="O2" value="5.33" spread="0.47"/>
                    <measurement group_id="O3" value="3.50" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" spread="1.02"/>
                    <measurement group_id="O2" value="5.33" spread="0.47"/>
                    <measurement group_id="O3" value="4.00" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.81" spread="1.10"/>
                    <measurement group_id="O2" value="5.00" spread="0.82"/>
                    <measurement group_id="O3" value="3.67" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beck Depression Inventory II (BDI-II)</title>
        <description>Comparison between Group A, B, and C for BDI-II scores measured at baseline and weeks 12, 24, and 36. A total score of 0-10 = these ups and downs are considered normal, 11-16 = mild mood disturbance,17-20 = borderline clinical depression, 21-30 = moderate depression, 31-40 = severe depression, over 40 = extreme depression</description>
        <time_frame>Baseline, Week 12, Week 24, and Week 36 Post Randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Subjects reporting 10 weeks or less of benefit from onabotuliunumtoxinA.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Subjects reporting greater than 10 weeks of benefit from onabotuliunumtoxinA.</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Subjects reporting no or minimal of benefit from onabotuliunumtoxinA (3 weeks or less).</description>
          </group>
        </group_list>
        <measure>
          <title>Beck Depression Inventory II (BDI-II)</title>
          <description>Comparison between Group A, B, and C for BDI-II scores measured at baseline and weeks 12, 24, and 36. A total score of 0-10 = these ups and downs are considered normal, 11-16 = mild mood disturbance,17-20 = borderline clinical depression, 21-30 = moderate depression, 31-40 = severe depression, over 40 = extreme depression</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.62" spread="10.27"/>
                    <measurement group_id="O2" value="16.67" spread="6.13"/>
                    <measurement group_id="O3" value="11.83" spread="6.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.43" spread="9.20"/>
                    <measurement group_id="O2" value="11.00" spread="3.27"/>
                    <measurement group_id="O3" value="7.67" spread="2.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.48" spread="9.10"/>
                    <measurement group_id="O2" value="12.33" spread="5.44"/>
                    <measurement group_id="O3" value="7.00" spread="4.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.00" spread="9.19"/>
                    <measurement group_id="O2" value="7.00" spread="4.97"/>
                    <measurement group_id="O3" value="7.00" spread="4.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>State-Trait Anxiety Inventory (STAI)</title>
        <description>Comparison between Group A, B, and C for STAI scores measured at baseline and weeks 12, 24, and 36. Scores range from 20-80, with 20 indicating lower levels of anxiety most generally, and 80 indicating higher levels of anxiety most generally.</description>
        <time_frame>Baseline, Week 12, Week 24, and Week 36 Post Randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Subjects reporting 10 weeks or less of benefit from onabotuliunumtoxinA.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Subjects reporting greater than 10 weeks of benefit from onabotuliunumtoxinA.</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Subjects reporting no or minimal of benefit from onabotuliunumtoxinA (3 weeks or less).</description>
          </group>
        </group_list>
        <measure>
          <title>State-Trait Anxiety Inventory (STAI)</title>
          <description>Comparison between Group A, B, and C for STAI scores measured at baseline and weeks 12, 24, and 36. Scores range from 20-80, with 20 indicating lower levels of anxiety most generally, and 80 indicating higher levels of anxiety most generally.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.76" spread="17.97"/>
                    <measurement group_id="O2" value="43.67" spread="13.89"/>
                    <measurement group_id="O3" value="40.67" spread="7.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.05" spread="10.08"/>
                    <measurement group_id="O2" value="40.00" spread="6.53"/>
                    <measurement group_id="O3" value="36.50" spread="8.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.62" spread="9.73"/>
                    <measurement group_id="O2" value="38.00" spread="11.43"/>
                    <measurement group_id="O3" value="38.00" spread="6.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.86" spread="9.92"/>
                    <measurement group_id="O2" value="36.33" spread="6.94"/>
                    <measurement group_id="O3" value="38.33" spread="8.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Quality Question</title>
        <description>Comparison between Group A, B, and C for sleep quality scores measured at baseline and weeks 12, 24, and 36 post-randomization. A single sleep quality question was asked indicating quality of sleep over the past four weeks. The scale ranged from 1-5, with 1 being very poor quality and 5 being very good quality of sleep.</description>
        <time_frame>Baseline, Week 12, Week 24, and Week 36 Post Randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Subjects reporting 10 weeks or less of benefit from onabotuliunumtoxinA.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Subjects reporting greater than 10 weeks of benefit from onabotuliunumtoxinA.</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Subjects reporting no or minimal of benefit from onabotuliunumtoxinA (3 weeks or less).</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Quality Question</title>
          <description>Comparison between Group A, B, and C for sleep quality scores measured at baseline and weeks 12, 24, and 36 post-randomization. A single sleep quality question was asked indicating quality of sleep over the past four weeks. The scale ranged from 1-5, with 1 being very poor quality and 5 being very good quality of sleep.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.19" spread="1.01"/>
                    <measurement group_id="O2" value="3.33" spread="0.47"/>
                    <measurement group_id="O3" value="3.00" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.48" spread="0.85"/>
                    <measurement group_id="O2" value="3.67" spread="0.47"/>
                    <measurement group_id="O3" value="2.5" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.57" spread="0.95"/>
                    <measurement group_id="O2" value="3.33" spread="0.47"/>
                    <measurement group_id="O3" value="2.83" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.38" spread="1.05"/>
                    <measurement group_id="O2" value="3.67" spread="1.25"/>
                    <measurement group_id="O3" value="2.50" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Medication Usage</title>
        <description>Comparison of acute medication usage between Groups A, B, and C during baseline, Treatment Period 1, 2, and 3.</description>
        <time_frame>From day 1 (first day of baseline) to day 281 (84th day of injection cycle 3) plus or minus 12 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Subjects reporting 10 weeks or less of benefit from onabotuliunumtoxinA.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Subjects reporting greater than 10 weeks of benefit from onabotuliunumtoxinA.</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Subjects reporting no or minimal of benefit from onabotuliunumtoxinA (3 weeks or less).</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Medication Usage</title>
          <description>Comparison of acute medication usage between Groups A, B, and C during baseline, Treatment Period 1, 2, and 3.</description>
          <units>number of medications used</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.29" spread="10.92"/>
                    <measurement group_id="O2" value="12.00" spread="5.10"/>
                    <measurement group_id="O3" value="13.83" spread="5.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Period 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.53" spread="24.26"/>
                    <measurement group_id="O2" value="20.67" spread="9.03"/>
                    <measurement group_id="O3" value="36.00" spread="19.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Period 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.33" spread="20.98"/>
                    <measurement group_id="O2" value="26.33" spread="10.08"/>
                    <measurement group_id="O3" value="28.33" spread="16.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Period 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.71" spread="18.77"/>
                    <measurement group_id="O2" value="9.67" spread="6.60"/>
                    <measurement group_id="O3" value="28.00" spread="16.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Consistency of Response to onbotulinumtoxinA Over Three Injection Cycles</title>
        <description>Compare the consistency of duration of onabotulinumtoxinA response by the group assignment at 12 weeks to assessments at 24, and 36 weeks evaluations as measured by the number of responders. A responder is defined as a 30% reduction from baseline in the number of headache days.</description>
        <time_frame>Weeks 12, 24, and 36 Post Randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Subjects reporting 10 weeks or less of benefit from onabotuliunumtoxinA.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Subjects reporting greater than 10 weeks of benefit from onabotuliunumtoxinA.</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Subjects reporting no or minimal of benefit from onabotuliunumtoxinA (3 weeks or less).</description>
          </group>
        </group_list>
        <measure>
          <title>Consistency of Response to onbotulinumtoxinA Over Three Injection Cycles</title>
          <description>Compare the consistency of duration of onabotulinumtoxinA response by the group assignment at 12 weeks to assessments at 24, and 36 weeks evaluations as measured by the number of responders. A responder is defined as a 30% reduction from baseline in the number of headache days.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Period 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Period 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Period 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of onabotulinumtoxinA Over 3 Injection Cycles</title>
        <description>Compare duration of benefit of onabotulinumtoxinA response through 3 injection cycles as measured by headache days per week (including the last 4 weeks of every injection cycle). A percent of responders was calculated using a 30% reduction of the number of headache days compared to average number of headache per week during baseline.</description>
        <time_frame>Weeks 9, 10, 11, 12, 21, 22, 23, 24, 33, 34, 35, 36 Post Randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Subjects reporting 10 weeks or less of benefit from onabotuliunumtoxinA.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Subjects reporting greater than 10 weeks of benefit from onabotuliunumtoxinA.</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Subjects reporting no or minimal of benefit from onabotuliunumtoxinA (3 weeks or less).</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of onabotulinumtoxinA Over 3 Injection Cycles</title>
          <description>Compare duration of benefit of onabotulinumtoxinA response through 3 injection cycles as measured by headache days per week (including the last 4 weeks of every injection cycle). A percent of responders was calculated using a 30% reduction of the number of headache days compared to average number of headache per week during baseline.</description>
          <units>percentage of responders</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 9 Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10 Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 11 Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 21 Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 22 Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 23 Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 33 Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 34 Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 35 Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Neuronal Regrowth</title>
        <description>Compare neuronal regrowth in the skin biopsies with duration of benefit of onabotulinumtoxinA in Groups A, B, C from baseline to 12 weeks post randomization. Neuronal regrowth change was scored on a 0-3 point scale with 0 being no change from baseline in regrowth and 3 being significant change from baseline.</description>
        <time_frame>Baseline &amp; Week 12 Post Randomization</time_frame>
        <population>Only a subset of subjects (n = 14) completed this endpoint for the trial based on the protocol design.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Subjects reporting 10 weeks or less of benefit from onabotuliunumtoxinA.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Subjects reporting greater than 10 weeks of benefit from onabotuliunumtoxinA.</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Subjects reporting no or minimal of benefit from onabotuliunumtoxinA (3 weeks or less).</description>
          </group>
        </group_list>
        <measure>
          <title>Neuronal Regrowth</title>
          <description>Compare neuronal regrowth in the skin biopsies with duration of benefit of onabotulinumtoxinA in Groups A, B, C from baseline to 12 weeks post randomization. Neuronal regrowth change was scored on a 0-3 point scale with 0 being no change from baseline in regrowth and 3 being significant change from baseline.</description>
          <population>Only a subset of subjects (n = 14) completed this endpoint for the trial based on the protocol design.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Beta Tublin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".61" spread=".66"/>
                    <measurement group_id="O2" value="0.0" spread="0.0"/>
                    <measurement group_id="O3" value="1.17" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcitonin Gene-Related Peptide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" spread="1.01"/>
                    <measurement group_id="O2" value="0.0" spread="0.0"/>
                    <measurement group_id="O3" value="1.0" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SNAP25 (Synaptosomal-Associated Protein)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" spread="1.03"/>
                    <measurement group_id="O2" value="0.5" spread="0.5"/>
                    <measurement group_id="O3" value="0.67" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From day 1 (first day of baseline) to day 281 (84th day of injection cycle 3) plus or minus 12 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>onabotulinumtoxinA</title>
          <description>At visit 2, subjects will receive their first treatment at Day 29 (+/-3 days). All subjects will receive 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas. Injections will be repeated at day 113 (+/- 3 days) and at day 197 (+/- 3 days).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Expressive Aphasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Unsteady Gait</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Spontaneous Abortion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinus Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Strep Throat</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Weight Gain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Eyebrow Droop</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Eyebrow Heaviness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Roger Cay, M.D.</name_or_title>
      <organization>Clinvest/A Division of Banyan Group Inc.</organization>
      <phone>417-883-7889</phone>
      <email>rcady@banyangroupinc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

